Investors
About Us
Ventoux Biosciences, Inc. is working to transform under-served immuno-fibrotic diseases with a lead program in Dupuytren's disease. Founded in October 2022 by a patient directly impacted by Dupuytren's, our mission is to develop innovative, first-line pharmacologic therapies designed to delay disease progression and improve post-operative outcomes. At the forefront of our efforts is VEN-201, a patented, first-in-class immuno-fibrotic modulator. This innovative therapy aims to disrupt the pathological cycle driving fibrosis, potentially offering a disease-modifying treatment for Dupuytren’s at various stages, including reducing post-operative recurrence. Our award-winning team unites leading fibrosis and oncology drug discoverers, internationally recognized Dupuytren's researchers, clinical development and regulatory experts, and esteemed treatment specialists. Together, we leverage cutting-edge science, including multi-omic analysis, to address the significant unmet needs of patients worldwide. At Ventoux Biosciences, we are committed to advancing VEN-201 and reshaping the standard of care, improving the lives of millions affected by this progressive condition.
why invest
Ventoux Biosciences is dedicated to delivering exceptional investor value by pioneering innovative treatments for underserved fibrotic diseases, with a strategic focus on Dupuytren's disease. This common, chronic, and progressive condition currently lacks approved pharmacologic therapies to delay disease progression, leaving millions of patients without effective solutions. The current seed round is pivotal, as it focuses on evaluating our patented lead candidate, VEN-201, in human Dupuytren's tissue for proof of concept. This critical study aims to validate VEN-201’s anti-fibrotic activity in an ex vivo model—a key milestone as we advance toward IND-enabling studies and a Phase 1b trial. In parallel, this round will drive optimization and evaluation of VEN-201’s long-acting formulation, support key regulatory planning and FDA engagement, and strengthen our intellectual property portfolio. With these initiatives, Ventoux Biosciences is uniquely positioned to achieve a significant inflection point in the development of VEN-201 while laying the groundwork for long-term commercial success.
Join our mission
Join us in transforming Dupuytren's disease treatment. Whether you are an accredited investor, first-time investor, or passionate supporter, there's a way for you to be part of this groundbreaking journey. Please select the option below that best matches your investment goals.
Accredited Investment (Red D)
$25,000 minimum investment. Direct equity ownership opportunity. Schedule an introductory meeting to learn more.
Community InvesTment (Reg CF)
$100 minimum investment. Own equity through WeFunder’s special purpose vehicle.
Be Part of the Momentum
We are at a key stage in developing transformational treatments for Dupuytren’s disease. Join our growing community through multiple paths:
- Invest in innovation through equity ownership (Reg-D or Reg-CF)
- Support our GoFund Me through direct donations
- Listen to “Hands of Change” podcast – a Dupuytren’s disease podcast, supported by Ventoux Biosciences
- Shop the “Hands of Change” store to help raise disease awareness. Sale proceeds support Ventoux Bioscieces research